Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15604413 | 0.82 | GAA (0.46) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL25946692 | 0.79 | HMGCR (0.41) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL20629674 | 0.78 | ALDH1A1 (0.39) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL11523073 | 0.77 | GAA (0.46) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL27944153 | 0.77 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL5323393 | 0.76 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL29034716 | 0.76 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| T-Butylacetic Acid SCHEMBL15106943 | 0.76 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL5730591 | 0.76 | GAA (0.38) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL9138775 | 0.76 | GAA (0.56) | GAACYP2C19TSHRCYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0133673-B1 | MEDICAMENTS CONTAINING VALEPOTRIATHYDRINES | Kali-Chemie Pharma GmbH (DE) | 1987-06-24 | — | — | EP | claimed |
| WO-2021095202-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, METHOD FOR FORMING MULTILAYER COATING FILM, ESTER COMPOUND, AND POLYMER | 共栄社化学株式会社 | 2021-05-20 | — | — | WO | disclosed |
| US-10751291-B2 | Nanoparticulate compositions comprising interferon gamma and losartan for immunotherapy | YALE UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180200196-A1 | Modular Particulars for Immunotherapy | IMMUNOVA LLC | 2018-07-19 | — | — | US | disclosed |
| US-9884026-B2 | Modular particles for immunotherapy | YALE UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| EP-1238704-B1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEM (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1433527-B1 | CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | DAICEL CHEM (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7759515-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-7368615-B2 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | ISHII YASUTAKA | 2006-02-09 | — | — | US | disclosed |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1459804-A1 | CATALYSTS COMPRISING CYCLIC ACYLUREA COMPOUNDS AND PROCESSES FOR PRODUCTION OF ORGANIC COMPOUNDS WITH THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1433527-A1 | CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040053778-A1 | Catalyst comprised of n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1238704-A2 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | Daicel Chemical Industries, Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-0133673-B1 | MEDICAMENTS CONTAINING VALEPOTRIATHYDRINES | Kali-Chemie Pharma GmbH (DE) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200196-A1 | Modular Particulars for Immunotherapy | CD47, ICOS, LY96 | HMGCR 1224/4885CHRM1 4182/4885TBXA2R 2247/4885 |
| US-10751291-B2 | Nanoparticulate compositions comprising interferon gamma and losartan for immunotherapy | IFNG, IL2, IFNAR1 | HMGCR 1647/4885CHRM1 3216/4885TBXA2R 1139/4885 |
| US-20020128149-A1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | NOX4, POR, NOX1 | HMGCR 2104/4885CHRM1 1680/4885TBXA2R 2713/4885 |
| US-20060030716-A1 | Catalyst comprising cyclic acylurea compound and process for producing organic compounds using the catalyst | MOGAT2, HAT1, ACOX1 | HMGCR 537/4885CHRM1 3154/4885TBXA2R 1086/4885 |
| US-20050020439-A1 | Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same | MOGAT2, ACSS2, ACOX1 | HMGCR 619/4885CHRM1 3161/4885TBXA2R 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.